CO6270322A2 - Usos terapeuticos de compuestos que tienen actividad combinada de sert 5-ht3 y 5-ht1a - Google Patents

Usos terapeuticos de compuestos que tienen actividad combinada de sert 5-ht3 y 5-ht1a

Info

Publication number
CO6270322A2
CO6270322A2 CO10057476A CO10057476A CO6270322A2 CO 6270322 A2 CO6270322 A2 CO 6270322A2 CO 10057476 A CO10057476 A CO 10057476A CO 10057476 A CO10057476 A CO 10057476A CO 6270322 A2 CO6270322 A2 CO 6270322A2
Authority
CO
Colombia
Prior art keywords
disorder
depression
disease
syndrome
pain
Prior art date
Application number
CO10057476A
Other languages
English (en)
Inventor
Nicholas Moore
Marianne Dragheim
Aneil Batra
Jin Cho
Original Assignee
Lundbeck & Co As H
Takeda Pharmaceuticls North America North America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6270322(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H, Takeda Pharmaceuticls North America North America filed Critical Lundbeck & Co As H
Publication of CO6270322A2 publication Critical patent/CO6270322A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan nuevos usos farmacéuticos de la 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y de sus sales aceptables para uso farmacéutico.1.- Un método para el tratamiento de una enfermedad seleccionada entre: trastorno del ritmo circadiano; dificultades para conciliar el sue±o; despertares nocturnos; despertares de madrugada; apnea del sue±o; sindrome de hipopnea; depresion severa; trastorno distimico; ciclotimia; depresion postrante; depresion atipica; trastorno del estado de animo asociado con un trastorno médico generalizado; trastorno del estado de animo inducido por sustancias; depresion recurrente; depresion de episodio ·nico; depresion pediatrica; depresion post-apoplejia; trastorno disforico peri-, pre- o post-menopausico; trastorno afectivo estacional (TAE); agresion y agitacion en la demencia o la enfermedad de Alzheimer; el espectro de trastornos compulsivos y de atencion en el TDAH, autismo o sindrome de Asperger; leucariosis; enfermedad de tos vasos capilares; depresion asociada con abuso, irritabilidad, hostilidad, trastornos del sue±o, fatiga, enfermedad de Huntington, esclerosis m·ltiple, ansiedad depresion por ansiedad), dolor, dolor del tracto gastrointestinal o sindrome de colon irritable (SCl); trastorno de ansiedad general asociada con dolor; trastorno del control de los impulsos; trastorno explosivo intermitente; cleptomania; piromania; adiccion al juego; tricotilomania; sintomas negativos de la esquizofrenia; deterioro cognitivo leve; demencia vascular; deterioro cognitivo asociado al sindrome de Down, mutaciones del gen tph, TDAH, epilepsia, lesion traumatica cerebral o sindrome de Asperger; agresion y agitacion en la demencia y en la enfermedad de Alzheimer; sindrome de fatiga cronica; trastorno relacionado con el estrés; estrés agudo; estrés; agotamiento ("burn-out"); resistencia a la insulina asociada con la hiperactividad del eje HPA; ...
CO10057476A 2007-11-13 2010-05-13 Usos terapeuticos de compuestos que tienen actividad combinada de sert 5-ht3 y 5-ht1a CO6270322A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701607 2007-11-13
DKPA200701788 2007-12-14
DKPA200801300 2008-09-17

Publications (1)

Publication Number Publication Date
CO6270322A2 true CO6270322A2 (es) 2011-04-20

Family

ID=40170671

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10057476A CO6270322A2 (es) 2007-11-13 2010-05-13 Usos terapeuticos de compuestos que tienen actividad combinada de sert 5-ht3 y 5-ht1a

Country Status (30)

Country Link
US (5) US9278096B2 (es)
EP (3) EP2431039B1 (es)
JP (2) JP5603244B2 (es)
KR (1) KR101536023B1 (es)
CN (1) CN102014908A (es)
AR (1) AR069260A1 (es)
AT (1) ATE537829T1 (es)
AU (1) AU2008323390B2 (es)
BR (1) BRPI0820474B8 (es)
CA (1) CA2705163C (es)
CL (1) CL2008003363A1 (es)
CO (1) CO6270322A2 (es)
CY (2) CY1112646T1 (es)
DK (2) DK2219647T4 (es)
EA (1) EA027783B1 (es)
ES (2) ES2379419T5 (es)
HR (2) HRP20120144T4 (es)
HU (1) HUE029588T2 (es)
IL (1) IL205466A (es)
LT (1) LT2431039T (es)
MX (1) MX2010004688A (es)
NZ (1) NZ585247A (es)
PL (2) PL2431039T3 (es)
PT (2) PT2431039T (es)
RS (2) RS52256B2 (es)
SG (1) SG10201405001XA (es)
SI (2) SI2219647T2 (es)
TW (1) TW200932233A (es)
WO (1) WO2009062517A1 (es)
ZA (1) ZA201003350B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
DK2470166T3 (da) 2009-08-24 2013-09-08 Lundbeck & Co As H Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
EP2667715B1 (en) * 2011-01-27 2017-07-19 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
US9274127B2 (en) 2011-07-21 2016-03-01 Meijo University Method for determining depression, kit for analyzing serotonin transporter, and kit for analyzing ubiquitinated serotonin transporter in blood
GEP201706739B (en) * 2012-12-13 2017-09-25 H Lundbeck As Compositions comprising vortioxetine and donepezil
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
CN105339361A (zh) * 2013-05-31 2016-02-17 斯洛文尼亚莱柯制药股份有限公司 用于合成1-(2-((2，4-二甲基苯基)硫代)苯基)哌嗪的新方法
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN105828821B (zh) * 2013-12-20 2019-04-09 H.隆德贝克有限公司 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
BR112018000841A8 (pt) * 2015-07-17 2022-11-22 Pasteur Institut Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE60219521T2 (de) * 2001-12-20 2007-08-16 H. Lundbeck A/S Aryloxyphenyl und arylsulfanylphenylderivate
JP4667366B2 (ja) 2003-04-04 2011-04-13 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤としての４−（２−フェニルスルファニル−フェニル）−ピペリジン誘導体
US20060019938A1 (en) 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
DK2470166T3 (da) 2009-08-24 2013-09-08 Lundbeck & Co As H Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin

Also Published As

Publication number Publication date
US20240082239A1 (en) 2024-03-14
PL2219647T3 (pl) 2012-07-31
US20180161321A1 (en) 2018-06-14
HUE029588T2 (en) 2017-03-28
EP3115050A1 (en) 2017-01-11
US20160228430A1 (en) 2016-08-11
EP2219647B1 (en) 2011-12-21
KR101536023B1 (ko) 2015-07-10
CY1117978T1 (el) 2017-05-17
CA2705163C (en) 2013-02-12
EP2431039B1 (en) 2016-07-20
TW200932233A (en) 2009-08-01
CN102014908A (zh) 2011-04-13
HRP20161121T1 (hr) 2017-01-27
EP2431039A1 (en) 2012-03-21
DK2431039T3 (en) 2016-09-26
IL205466A (en) 2014-06-30
SI2431039T1 (sl) 2017-01-31
ES2379419T3 (es) 2012-04-25
AU2008323390A1 (en) 2009-05-22
US9278096B2 (en) 2016-03-08
RS52256B2 (sr) 2020-11-30
SI2219647T1 (sl) 2012-06-29
CA2705163A1 (en) 2009-05-22
ZA201003350B (en) 2011-08-31
JP5841636B2 (ja) 2016-01-13
RS55147B1 (sr) 2016-12-30
US20110201617A1 (en) 2011-08-18
RS52256B (en) 2012-10-31
ATE537829T1 (de) 2012-01-15
JP2011503125A (ja) 2011-01-27
ES2591110T3 (es) 2016-11-24
IL205466A0 (en) 2010-12-30
KR101536023B9 (ko) 2023-03-29
HRP20120144T1 (en) 2012-04-30
US9744166B2 (en) 2017-08-29
SG10201405001XA (en) 2014-10-30
BRPI0820474B8 (pt) 2021-05-25
EP2219647B2 (en) 2020-07-29
BRPI0820474B1 (pt) 2020-08-04
BRPI0820474A2 (pt) 2017-05-23
CL2008003363A1 (es) 2009-06-05
CY1112646T1 (el) 2016-02-10
US20210093631A1 (en) 2021-04-01
DK2219647T3 (da) 2012-03-19
NZ585247A (en) 2012-03-30
JP2014193891A (ja) 2014-10-09
KR20100099115A (ko) 2010-09-10
AR069260A1 (es) 2010-01-06
EA027783B1 (ru) 2017-09-29
ES2379419T5 (es) 2021-05-04
US11628166B2 (en) 2023-04-18
PT2219647E (pt) 2012-03-16
LT2431039T (lt) 2016-10-10
DK2219647T4 (da) 2020-09-28
EA201070598A1 (ru) 2010-10-29
JP5603244B2 (ja) 2014-10-08
HRP20120144T4 (hr) 2020-11-13
SI2219647T2 (sl) 2020-11-30
EP2219647A1 (en) 2010-08-25
AU2008323390B2 (en) 2013-10-24
PL2431039T3 (pl) 2016-12-30
PT2431039T (pt) 2016-09-29
WO2009062517A1 (en) 2009-05-22
MX2010004688A (es) 2010-09-09

Similar Documents

Publication Publication Date Title
CO6270322A2 (es) Usos terapeuticos de compuestos que tienen actividad combinada de sert 5-ht3 y 5-ht1a
Wennberg et al. Sleep disturbance, cognitive decline, and dementia: a review
Waite et al. The ECT handbook
Blackman et al. Paroxysmal autonomic instability with dystonia after brain injury
Abad et al. Diagnosis and treatment of sleep disorders: a brief review for clinicians
Saker et al. Benign paroxysmal positional vertigo subsequent to sinus lift via closed technique
Szaulińska et al. Obstructive sleep apnea in severe mental disorders
Grounds et al. Intensive Care Society Review of Best Practice for Analgesia and Sedation in the Critical Care
Kong et al. Altered heart rate variability during sleep in mild cognitive impairment
CO6290669A2 (es) Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina
US20230091682A1 (en) Cognitive disorder prevention and therapy
CO6220958A2 (es) Formulaciones liquidas de sales de 4-[2-(4-metilfenilsulfanil)fenil]-piperazina
Holbert et al. Sleep and schizophrenia
Wilson et al. Treatment of insomnia
Ali et al. Pain management by a combination of tramadol, haloperidol and carbamazepine in Iraqi burn patients
Satoh et al. Severe bradycardia possibly due to a local anesthetic oral mucosal injection during general anesthesia
Renton Prevention and optimal management of peri-surgical pain in dentistry
TIHACEK‐SOJIC et al. The effectiveness of oral appliances in elderly patients with obstructive sleep apnoea treated with lorazepam–a pilot study
Hategan et al. Other Major and Mild Neurocognitive Disorders: Parkinson Disease, Atypical Parkinsonism, and Traumatic Brain Injury Types
Park et al. The difference of the nurses' perception on the importance and performance of rehabilitation nursing service
Hardy Prescribing for depression in primary care
Hosseini et al. Fluoxetine-induced Hypotension: A Case Report
Davoudi-Monfared et al. Citalopram induced nightmare in an elderly man: A case report
Gao et al. 1159 Sleep Traits And Incident Delirium During A Decade Of Follow-up In 173,000 Participants
Manber et al. Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant

Legal Events

Date Code Title Description
FC Application refused